These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10036894)

  • 1. [Postoperative respiratory failure resulting from perioperative withdrawal of antiparkinsonian medications].
    Koganei H; Tanaka S; Iijima K; Horikawa Y; Tanaka O
    Masui; 1999 Jan; 48(1):70-2. PubMed ID: 10036894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report.
    Defazio G; De Mari M; De Salvia R; Lamberti P; Giorelli M; Livrea P
    Clin Neuropharmacol; 1999; 22(5):292-4. PubMed ID: 10516881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative hyperthermic syndrome following antiparkinsonian drugs withdrawal: the pitfall of enteral refeeding.
    Casier I; Jeanjean A; Hantson P
    Anaesth Intensive Care; 2013 Nov; 41(6):814-5. PubMed ID: 24180734
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal.
    Young CC; Kaufman BS
    J Clin Anesth; 1995 Dec; 7(8):652-6. PubMed ID: 8747565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Levodopa withdrawal symptoms in a non-Parkinsonian patient].
    Cabo-López I; García-Bermejo P; García-Ruiz PJ
    Rev Neurol; 2007 Aug 1-15; 45(3):190. PubMed ID: 17661281
    [No Abstract]   [Full Text] [Related]  

  • 9. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
    García-Escrig M; Bermejo Pareja F; Fernández Ponsatí JT
    Med Clin (Barc); 1999 Feb; 112(7):245-50. PubMed ID: 10220750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral subthalamic nucleus stimulation results in reversal of alopecia in Parkinson's disease.
    Yamada K; Goto S
    Parkinsonism Relat Disord; 2004 Aug; 10(6):353-5. PubMed ID: 15261876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
    Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
    Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE; Antic R; Thompson PD
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.